
Hans Bishop, CEO and Co-founder of Juno Therapeutics who helped set up the company in 2013 and has since grown …

Celgene has already started off the year with a bang, announcing a deal with Impact Biomedicines worth a potential $7 …

Just last week Novartis revealed it had applied to the FDA for a new indication in diffuse large B-cell lymphoma …

Celgene has invested $1 billion into Juno Therapeutics as part of a 10-year partnership aiming to study cures for cancer …

AstraZeneca posted a 1% increase in revenue in its first-quarter 2015 financials – and is investing the money to back …
Jennings becomes President of Beckman Coulter Diagnostics
Boyds expands Regulatory Affairs team to support growing demand
Sterling doubles ADC manufacturing capacity at Welsh facility
Femtosecond laser cuts lung tumour margin assessment time

